Skip to main content

Subdural Hematoma

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Arsenal Biosciences
Arsenal BiosciencesCA - South SF
1 program
NeoCast Embolic SystemN/A1 trial
Active Trials
NCT07541404Not Yet Recruiting150Est. Feb 2028
Medtronic
MedtronicNJ - Phillipsburg
1 program
Surgical ManagementN/A1 trial
Active Trials
NCT04402632Completed600Est. Apr 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Arsenal BiosciencesNeoCast Embolic System
MedtronicSurgical Management

Clinical Trials (2)

Total enrollment: 750 patients across 2 trials

NCT07541404Arsenal BiosciencesNeoCast Embolic System

MMA Embolization With NeoCast for Subacute and Chronic Subdural Hematoma

Start: Jul 2026Est. completion: Feb 2028150 patients
N/ANot Yet Recruiting
NCT04402632MedtronicSurgical Management

Embolization of the Middle Meningeal Artery With ONYX™ Liquid Embolic System for Subacute and Chronic Subdural Hematoma

Start: Oct 2020Est. completion: Apr 2025600 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.